MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
69.96%
Quick Ratio
69.96%
Cash Ratio
16.63%
Debt to Asset Ratio
137.56%
Unit: Dollar
Assets Breakdown
    • Cash and cash equivalents
    • Unbilled receivable
    • Property and equipment, net
Liabilities Breakdown
    • Accumulated deficit
    • Additional paid-in capital
    • Accounts payable
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
676,704
745,482
4,310,354
1,673,218
Unbilled receivable
416,811
-
420,345
4,411
Prepaid expenses and other current assets
1,752,695
1,263,058
2,511,769
1,250,641
Total current assets
2,846,210
2,008,540
7,242,468
2,928,270
Property and equipment, net
111,063
117,596
124,129
123,643
Other assets
-
41,667
85,882
127,551
Total assets
2,957,273
2,167,803
7,452,479
3,179,464
Accounts payable
1,977,629
1,610,186
3,267,610
463,458
Accrued expenses and other liabilities
1,893,635
980,780
993,411
1,453,555
Notes payable and accrued interest
196,842
245,849
306,708
387,702
Total current liabilities
4,068,106
2,836,815
4,567,729
2,304,715
Other long-term liabilities
-
-
-
35
Total long-term liabilities
-
-
-
35
Total liabilities
4,068,106
2,836,815
4,567,729
2,304,750
Common stock, 0.0001 par value, 250,000,000 shares authorized at june 30, 2026 and december 31, 2025 16,227,524 and 4,574,983 shares issued at june 30, 2026 and december 31, 2025, respectively 16,227,518 and 4,574,977 shares outstanding at june 30, 2026 and december 31, 2025, respectively
1,624
929
459
320
Additional paid-in capital
145,063,802
142,935,443
142,933,260
138,155,394
Accumulated deficit
-145,847,123
-143,276,414
-139,719,999
-136,952,351
Total ensysce biosciences, inc. stockholders equity (deficit)
-781,697
-340,042
3,213,720
1,203,363
Noncontrolling interests in stockholders equity (deficit)
-329,136
-328,970
-328,970
-328,649
Total stockholders equity (deficit)
-1,110,833
-669,012
2,884,750
874,714
Total liabilities and stockholders equity (deficit)
2,957,273
2,167,803
7,452,479
3,179,464
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Prepaid expenses andother current assets$1,752,695 (-6.02%↓ Y/Y)Cash and cashequivalents$676,704 (-69.40%↓ Y/Y)Unbilled receivable$416,811 (-65.41%↓ Y/Y)Total current assets$2,846,210 (-46.11%↓ Y/Y)Property and equipment,net$111,063 Accumulated deficit-$145,847,123 (-9.48%↓ Y/Y)Total assets$2,957,273 (-46.95%↓ Y/Y)Total ensyscebiosciences, inc....-$781,697 (-123.07%↓ Y/Y)Noncontrolling interests instockholders equity...-$329,136 (-0.15%↓ Y/Y)Additional paid-in capital$145,063,802 (6.19%↑ Y/Y)Common stock, 0.0001par value,...$1,624 (573.86%↑ Y/Y)Total liabilities andstockholders equity...$2,957,273 (-46.95%↓ Y/Y)Total stockholdersequity (deficit)-$1,110,833 (-136.30%↓ Y/Y)Total liabilities$4,068,106 (61.82%↑ Y/Y)Total currentliabilities$4,068,106 (61.88%↑ Y/Y)Accounts payable$1,977,629 (89.64%↑ Y/Y)Accrued expenses andother liabilities$1,893,635 (81.10%↑ Y/Y)Notes payable andaccrued interest$196,842 (-53.63%↓ Y/Y)

Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences, Inc. (ENSC)